

Angel Artal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7075022/publications.pdf>

Version: 2024-02-01

21
papers

6,522
citations

623734

14
h-index

677142

22
g-index

23
all docs

23
docs citations

23
times ranked

7339
citing authors

#	ARTICLE	IF	CITATIONS
1	Massive Hemoptysis after the First Administration of Pembrolizumab in a Strongly Positive, Centrally Located NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, e76-e77.	1.1	5
2	Chemotherapy-associated anemia in patients with lung cancer: an epidemiological, retrospective and multicenter study. <i>Future Oncology</i> , 2015, 11, 1665-1674.	2.4	6
3	Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel. <i>Future Oncology</i> , 2015, 11, 267-277.	2.4	17
4	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 239-246.	10.7	4,943
5	Management of lung cancer-associated anaemia: the Spanish Lung Cancer Anaemia Survey (SLCAS). <i>Clinical and Translational Oncology</i> , 2011, 13, 328-334.	2.4	4
6	SEOM clinical guidelines for the treatment of small-cell lung cancer. <i>Clinical and Translational Oncology</i> , 2010, 12, 27-31.	2.4	2
7	Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: Is a hemogram on day 8 essential?. <i>Lung Cancer</i> , 2010, 68, 415-419.	2.0	8
8	Bilateral Choroidal Metastases Revealing an Advanced Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2009, 88, 1013-1015.	1.3	19
9	Long-Term Survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non-Small-Cell Lung Cancer Patients: The Spanish Lung Cancer Group Trial 9901. <i>Journal of Clinical Oncology</i> , 2007, 25, 4736-4742.	1.6	104
10	Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2005, 16, 597-601.	1.2	23
11	Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2004, 10, 1318-1325.	7.0	345
12	Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2004, 15, 1194-1203.	1.2	270
13	Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study. <i>Lung Cancer</i> , 2003, 39, 201-207.	2.0	14
14	Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non-Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 3207-3213.	1.6	177
15	Phase II Trial of Paclitaxel Plus Gemcitabine in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 1071-1077.	1.6	45
16	Brain Metastases from Colorectal Carcinoma. <i>Tumori</i> , 2001, 87, 332-334.	1.1	17
17	Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors. <i>Anti-Cancer Drugs</i> , 2001, 12, 713-717.	1.4	20
18	Preoperative High-Dose Cisplatin Versus Moderate-Dose Cisplatin Combined with Ifosfamide and Mitomycin in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Results of a Randomized Multicenter Trial. <i>Clinical Lung Cancer</i> , 2000, 1, 287-293.	2.6	12

#	ARTICLE	IF	CITATIONS
19	Prognostic impact of bulky mediastinal lymph nodes (N2 > 2.5 cm) in patients with locally advanced non-small-cell lung cancer (LA-NSCLC) treated with platinum-based induction chemotherapy. <i>Lung Cancer</i> , 2000, 30, 107-116.	2.0	12
20	Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 12-12.	1.6	438
21	Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 1998, 22, 139-148.	2.0	37